Prescription medicine
Enalapril and hydrochlorothiazide Brand names: Vaseretic
Enalapril and hydrochlorothiazide (Vaseretic) is a prescription medicine with an FDA approval on record since 1986. FDA's NDC Directory lists it from 2 generic labelers, and pharmacies paid $0.209 per enalapril-hydrochlorothiazide 10-25 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- Boxed warning
Check it at the source: the enalapril and hydrochlorothiazide FDA label on DailyMed (effective August 31, 2020, Bausch Health US, LLC); the NDA 19221 record on Drugs@FDA; every enalapril and hydrochlorothiazide label on DailyMed.
Highlights of the record
FDA label of August 31, 2020; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
FETAL TOXICITY.
See full prescribing information for complete boxed warning.
When pregnancy is detected, discontinue VASERETIC ® as soon as possible.
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS: Fetal Toxicity
Used for
From the label: indications and usageVASERETIC is indicated for the treatment of hypertension.
Forms and strengths
- 5 mg / 12.5 mg
- 10 mg / 25 mg
Tablet.
On the market
- Earliest approval on file
- October 31, 1986 Vaseretic, Bausch; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 7 first September 18, 2001; 2 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 3 of which 2 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.209 per tablet Enalapril-hydrochlorothiazide 10-25 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 2 since 2014 0 Class I among all firms' recalls; latest May 29, 2015
- FAERS reports
- 911 through July 30, 2026
What is enalapril and hydrochlorothiazide used for?
From the label: indications and usageVASERETIC is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial treatment (see DOSAGE AND ADMINISTRATION ). In using VASERETIC, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see WARNINGS ). […]
Conditions named in the indications of enalapril and hydrochlorothiazide's FDA labels, with every medicine labeled for each:
From other enalapril and hydrochlorothiazide labelsHigh blood pressure: INDICATIONS AND USAGE VASERETIC is indicated for the treatment of hypertension.
FDA pharmacologic class: Angiotensin Converting Enzyme Inhibitor and Thiazide Diuretic.
Source: FDA drug label (Vaseretic), Bausch Health US, LLC, effective August 31, 2020 (SPL set bf3007e2-8fcc-48de-8fd5-55e95033d62f), via openFDA; the full label on DailyMed
Is there a generic for enalapril and hydrochlorothiazide (Vaseretic)?
The FDA approved the first generic enalapril and hydrochlorothiazide on September 18, 2001. 7 generic applications are approved; 2 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists enalapril and hydrochlorothiazide from 2 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1986 earliest approval on file
- 2001 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for enalapril and hydrochlorothiazide (Vaseretic)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.209 per Enalapril-hydrochlorothiazide 10-25 mg tablet, up 17% from $0.179 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Enalapril-hydrochlorothiazide 5-12.5 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Enalapril-hydrochlorothiazide 10-25 mg tablet | Generic | $0.209 per tablet | $6.26 | +17% |
| Enalapril-hydrochlorothiazide 5-12.5 mg tablet | Generic | $0.170 per tablet | $5.10 | -1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has enalapril and hydrochlorothiazide been recalled?
The FDA's Enforcement Report lists 2 recalls naming enalapril and hydrochlorothiazide since 2014: 0 Class I (the most serious), 1 Class II, 1 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| May 29, 2015 | Class II | Apotex Inc. | Failed Content Uniformity Specifications: The product may not meet the limit for blend uniformity specification. |
| May 21, 2014 | Class III | Valeant Pharmaceuticals North America LLC | Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package outset |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the enalapril and hydrochlorothiazide label say about other medicines?
The enalapril and hydrochlorothiazide label names 18 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aliskiren | contraindications | Do not co-administer aliskiren with VASERETIC in patients with diabetes (see PRECAUTIONS, Drug Interactions ). |
| Amiloride | drug interactions | Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. |
| Captopril | warnings | Neutropenia/Agranulocytosis Another angiotensin converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment especially if they also have a collagen vascular disease. |
| Cholestyramine | drug interactions | Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively. Corticosteroids, ACTH Intensified electrolyte depletion, particularly hypokalemia. |
| Colestipol | drug interactions | Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively. Corticosteroids, ACTH Intensified electrolyte depletion, particularly hypokalemia. |
| Epinephrine | warnings | Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway, should be promptly provided (see ADVERSE REACTIONS ). |
| Everolimus | drug interactions | Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see WARNINGS ). |
| Hydralazine | drug interactions | Other Cardiovascular Agents Enalapril has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions. |
| Indomethacin | drug interactions | In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving enalapril maleate. |
| Lithium | drug interactions | Lithium Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. |
| Methyldopa | drug interactions | Other Cardiovascular Agents Enalapril has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions. |
| Prazosin | drug interactions | Other Cardiovascular Agents Enalapril has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions. |
| Sacubitril and valsartan | contraindications | Do not administer VASERETIC within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS ). |
| Sirolimus | drug interactions | Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see WARNINGS ). |
Every other medicine the enalapril and hydrochlorothiazide label names
| Medicine named | Section | What the label says |
|---|---|---|
| Spironolactone | drug interactions | Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. |
| Sulindac | drug interactions | In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving enalapril maleate. |
| Temsirolimus | drug interactions | Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see WARNINGS ). |
| Triamterene | drug interactions | Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. |
Check enalapril and hydrochlorothiazide against other medicines
Source: FDA drug label (Vaseretic), Bausch Health US, LLC, effective August 31, 2020 (SPL set bf3007e2-8fcc-48de-8fd5-55e95033d62f), via openFDA; the full label on DailyMed
What do FAERS reports show for enalapril and hydrochlorothiazide?
The FDA Adverse Event Reporting System holds 911 reports that list enalapril and hydrochlorothiazide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 61 are coded as a death and 507 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as enalapril and hydrochlorothiazide?
56 other medicines are given the same way (oral) and in the same FDA class as enalapril and hydrochlorothiazide or labeled mainly for the same use (high blood pressure), the same class first. High blood pressure lists all 88 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Lisinopril | High blood pressure | 36 labelers | $0.0254 per tablet 20 mg tablet | No current entry |
| Amlodipine and benazepril | High blood pressure | 16 labelers | $0.114 per unit 10-20 mg | No current entry |
| Benazepril | High blood pressure | 21 labelers | $0.0789 per tablet 20 mg tablet | No current entry |
| Ramipril | High blood pressure | 17 labelers | $0.0707 per capsule 10 mg capsule | No current entry |
| Captopril | High blood pressure | 13 labelers | $0.228 per tablet 12.5 mg tablet | No current entry |
| Quinapril | High blood pressure | 9 labelers | n/a | In shortage |
| Fosinopril | High blood pressure | 7 labelers | $0.154 per tablet 10 mg tablet | No current entry |
| Trandolapril | High blood pressure | 5 labelers | $0.157 per tablet 1 mg tablet | No current entry |
Every medicine labeled for the same conditions as enalapril and hydrochlorothiazide
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to enalapril and hydrochlorothiazide
- 56 medicines for the same use
- Other ACE inhibitors
- the pharmacologic class, with prices and generics
- Enalapril and hydrochlorothiazide side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other